International Conference on Recent Advances in Precision Medicine and Population Health

 Website 

Dr. Huey-Kang Sytwu

Opening Remarks

Vice President, National Health Research Institutes, Taiwan

Dr. Hou-Chuan Chen

Opening Remarks

Deputy Superintendent, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan

Dr. Kung-Yee Liang

Special Lecture

President, National Health Research Institutes, Taiwan

Dr. Yik-Ying Teo

Opportunities and Challenges in the Precision Public Health of Non-Communicable Diseases

Dean, NUS Saw Swee Hock School of Public Health, SINGAPORE

Dr. Feza Korkusuz

Joint Cartilage Regeneration

Professor, Department of Sports Medicine, Hacettepe University, TURKEY

Dr. Shih-Feng Tsai

Big Data Analysis and Application for Precision Medicine

Distinguished Investigator, Institute of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan

Dr. Feng-Huei Lin

Bioengineering in Precision Medicine

Distinguished Investigator and Director, Institute of Biomedical Engineering and Nanomedicine National Health Research Institutes, Taiwan

Dr. Shu-Hsing Cheng

A multicenter, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine in Adult Patients with Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Attending Physician and Director, Department of Education and Research, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan

Dr. Chun-Yuan Lin

Aim to Next Generation Psychiatry

Attending Physician and Director, Department of General Psychiatry, Tsaotun Psychiatric Center, Ministry of Health and Welfare, Taiwan

Dr. Shiu-Feng Huang

Introduction of NHRI Biobank

Investigator and attending physician, Institute of Molecular and Genomic Medicine, National Health Research Institutes

Dr. Chien-Yu Cheng

Clinical Sample Fast-screening Evaluation and Examination for COVID-19

Attending Physician and Director, Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan

Dr. Hsiu-Hsueh Tseng

Rapid Execution of the Coronavirus Disease 2019 (COVID-19) Blood Sample Collection under the Guideline of National Biobank Consortium of Taiwan

Investigator, Biobank Provisional Office, Department of Education and Research, Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan

2020 ASCO20 Virtual Meeting (05/29-05/31 Scientific)

The ASCO20 Virtual Scientific Program is days away. Follow these tips and access meeting materials to ensure a successful and easy virtual experience.

Test Your Login in Advance

Don’t wait until the sessions start to log in for the first time. Make sure you’ll be able to access meeting content by logging in to the ASCO20 Virtual test page today. As a reminder, your username is sflin1@gmail.com.

For assistance, please contact ASCO Customer Service from 7:00 AM – 7:00 PM (ET) at customerservice@asco.org, 888-282-2552, or 703-299-0158.

Plan Ahead

On-demand content (including oral, poster, and poster discussion sessions, and track-based Clinical Science Symposia) will be available on ASCO Meeting Library starting at 8:00 AM (ET) on Friday, May 29.

Review the broadcast schedule to free your calendar for sessions you’re interested in. The broadcasts will be showing at am.asco.org from 9:30 AM – 5:30 PM (ET) on May 30 and 31. These sessions will be available on demand two hours after the broadcast.

Access Meeting Materials

Abstracts for the ASCO20 Virtual Scientific Program are now available on ASCO Meeting Library or as downloadable PDFs.

Meeting Videos and Slides will be available on ASCO Meeting Library for all registered attendees beginning May 29.


Read ASCO Daily News for updates before, during, and after the Scientific Program.

Browse the 2020 ASCO Educational Book for a preview of the ASCO20 Virtual Education Program, to be held August 8-10.

2020 ASCO20 Virtual Meeting (08/08-08/10 Education)

2020 ASCO20 Virtual  (HomePage)

Access Meeting Materials

Abstracts for the ASCO20 Virtual Scientific Program are now available on ASCO Meeting Library or as downloadable PDFs.  💖💜🙏🙆🙆🙆

Meeting Videos and Slides will be available on ASCO Meeting Library for all registered attendees beginning May 29.

Read ASCO Daily News for updates before, during, and after the Scientific Program.

Browse the 2020 ASCO Educational Book for a preview of the ASCO20 Virtual Education Program, to be held August 8-10.  💙💚💜💝

⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕⤕

國際會議連結網址

2022 The 20th International Symposium on Epstein-Barr virus (EBV) and Associated Diseases will be held in Siena, Italy, on July 3rd-6th, 2022. (http://www.congressi.unisi.it/ebvconferencesiena/)

2020 EBV20 (Hokkaido, Japan) (Postponed due to pandemics)

2020 AACR56 virtual meeting  04/27-04/28   06/22-06/24

2020 ASCO20 virtual meeting 05/29-05/31 (Scientific) 08/08-08/10 (Education)

2019 ASCO19 (Chicago, USA)  index page

2019 KSHV22 workshop (New York, USA) (Link)

2018 EBV and KSHV 2018 (Link)

• Chicago Airport Shuttle Bus (Link)
• Meeting notes by SFL (index page)

GRC NPC 2018 (Link)

• HKU AoE (Link)
• Meeting notes by SFL (index page)

GRC NPC 2016 (Link)

• Meeting notes by SFL and Ming-Han (index page)

_________________________

Conferences and meetings in EBV Association (U. Sussex, 2018/8/8 註冊) (Link)

Biannual International Symposium on Nasopharyngeal Carcinoma

• 7th 2015 Yogyakarta – Indonesia (Link) (Proceedings of the meeting)
• 6th 2013 Istanbul, Turkey (Link)
• 5th 2011 Penang, Malaysia (Link)
• 4th 2009 
• 3rd 2007
• 2nd 2005
• 1st 2003

2020 AACR Virtual Meeting - II (06/22 ~ 06/24)

Back to search page (較簡潔)

Home for virtual meeting II (https://aacr20vm2.onlineeventpro.freeman.com/)
(MyAACR sflin1 | Gn9)

06/22 10:00-12:20 AM
SESSION PL01 - Opening Plenary Session: Turning Science into Lifesaving Care

2020 AACR Virtual Meeting - I (04/27 ~ 04/28)

AACR 2020 Virtual Meeting I 


Virtual Meeting Announcement site  (find abstracts easier in this site)
Search by "tumor microenvironment" ---->  by Date ----> 04/27 nothing interesting

04/28 (https://www.abstractsonline.com/pp8/#!/9045/session/838)
Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease

• 5702 - A spatially resolved single cell atlas of the human breast (Tapsi Kumar & Kai Kessenbrock)

Abstract

The human breast consists of lobules connected to an intricate network of ducts that are surrounded by fatty tissues, designed to produce and transport milk to nourish offspring. Histopathology has identified 10 major cell types based on morphological features but have provided limited information on cell states - the transcriptional programs of cell types that reflect different biological functions. In this study we have generated an unbiased ‘cell atlas’ of the normal human breast to define the cell types and cell states using single cell RNA sequencing and spatial transcriptomics methods. We performed 3’ microdroplet based single cell and nuclei RNA sequencing of 248,687 stromal cells and 89,301 nuclei from 24 women with pathologically normal breast tissues that were collected from mastectomies and reduction mammoplasties. Unbiased expression analysis identified four major cell types: adipocytes, epithelial cells (luminal and basal), fibroblasts and endothelial cells and defined their transcriptional programs. Additionally, 8 minor cell types were identified in the breast, including macrophages, T-cells, natural killer cells, mast cells, pericytes, apocrine cells, neurons and smooth muscle cells. Our data revealed hundreds of novel markers of these cell types and defined their transcriptional programs and cell states. Most cell types had multiple transcriptional programs including luminal epithelial cells (hormone receptor positive and secretory), basal epithelial cells (myoepithelial or basal), endothelial cells (E1, E2, E3), myeloid cells, T-cells and fibroblasts (F1-F4) and provided insight into developmental lineages. We further delineated the spatial organization of these cell types and cell states within the tissue architecture using spatial transcriptomics assay. The breast cell atlas data provides an invaluable normal reference for the research community to understand how normal cell types are reprogrammed in diseases such as breast cancer.

2019 ASCO Meeting

CancerLinQ: 

CancerLinQ LLC is a not-for-profit subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operation of the CancerLinQ initiative.[1]. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. This program was created to give oncologists a robust quality monitoring system that collects and analyzes data from all patient encounters using Big data [1]

CancerLinq integrates EHR systems to improve care and fight cancer, bridging this information allows for greater knowledge-sharing and for better research opportunities to cure cancer. Only 3% of cancer patients take part in experimental medicine and clinical trials. That means there is none, or little, information of the other 97%. CancerLinQ aims to overcome this issue by gathering data from all oncologists and integrating it into one shared database.[2]

FASCO: 
ASCO has announced the designation of Fellow of the American Society of Clinical Oncology, otherwise known as FASCO. Formerly called the ASCO Statesman Award and launched in 2007, the distinction is designed to honor ASCO’s most active volunteer members.

“The FASCO status represents recognition for the most dedicated and active volunteer members inside the organization,” said Allen S. Lichter, MD, CEO of ASCO. “These are people who have given of themselves tirelessly over a long period of time. They represent the very best of our organization.”

[AWARD TALKs]

Allen S. Lichter Visionary Leader Award to Ian Tannock, MD, PhD (Princess Margaret Cancer Centre, University of Toronto. )
Clinical trials and their application: should we believe what we read?

2019 福爾摩沙免疫春季學校與會議, FISS

FISS: Formosa Immunology Spring School & Symposium 2019 (Apr 12-13)

[會議報名]
尚未開放 預計2019年1月開放報名
開放所有人士報名
地點: 林口長庚紀念醫院
歡迎加入Facebook粉絲頁"I-Club"，追蹤會議消息

[春季學校註冊資訊]
報名資格:
台灣生物醫學, 免疫相關學系之: A. 博士班學生; B. 碩士班學生; C. 博士後; D. 研究助理; E. 牙/醫學系學生; F. 牙/醫生; G. 其他任何修習過大學程度免疫學 (請於CV中註明)。
正在或在一年之內曾在實驗室工作並取得實驗室主持人推薦信 (見申請文件)。
入選學員需全程參與免疫學校活動以及國際研討會。
報名日期: 2018年10月15日-11月30日

申請文件:
完整填寫下載四份文件 templates (CV, Personal Statement, Research Abstract,
Recommendation letter from Lab head)後, 請匯集儲存成一份PDF文件
文件檔名應為: FISS_Last name_First name initial_分類(見報名資格#1)
Example: Li-Fan Lu, Postdoc. - The file name should be: "FISS_Lu_LF_C"

CV
Personal Statement
Research Abstract
Recommendation Letter

甄選條件:
依申請文件條件由國外審核委員擇優甄選。
最後選取總數為30位學員, 在全部申請者中條件接近下, 力求男女比例以及報名各分類人數比例平衡。
申請文件不齊全者 ，完全不予考慮。
所有錄取學員需準備Poster presentation, 另外審查委員會依Research Abstract擇優甄選學員做20分鐘 Oral presentation (15 min presentation + 5 min Q&A) 。
甄選結果於 2019年1月31日email通知。

報名費:
入選學員除需繳交$5000保證金外, 活動全程包含報名費以及食宿費用全免。
被評選優秀Poster以及Oral presentation的與會學員，會於國際研討會後頒發獎學金以茲鼓勵。

全程參與免疫學校活動以及國際研討會之學員, 在活動結束後三個月內, 保證金會全額退還。
*請點擊報名於報名期間 2018年 10月15日-11月30日 上傳所需完整文件*

2018 Madison Meeting Index Page

July 28 Saturday
Keynote Address 1 (Henle Lecture: Paul Lieberman)

July 29 Sunday

(Session 1) Gene Expression/Epigenetics (led by Ke Lan & Wolfgang Hammerschmidt)

• Global Changes in the Host B cell During the Pre-latent Phase of EBV Infection (Paulina Mrozek-Gorska)
• Single-Cell Analysis of Gammaherpesvirus Infection and Gene Expression (Lauren Oko)
• 3D architecture of host-pathogen genomic interactions during EBV reactivation (JJ Miranda)
• Modulation of Cellular CpG DNA Methylation by Kaposi’s Sarcoma Associated Herpesvirus (Guy Journo)
• Epstein-Barr Virus Nuclear Antigen EBNA-LP is Essential for Transforming Naive B Cells, and Supports the Activation of Viral Genes, but not EBNA2-Induced Cellular genes (Rob E. White)
• Polycomb Recruitment During Latency Establishment: A Comparative Study (Thomas Günther)

2018 GRC NPC Index page

0624 (Sunday night)

• Prof George SW Tsao: 186 participants (66 China, 44 Hong Kong, 20 Industry)
• Keynote Session: Viruses, Cancer and Stem Cell [06/24 PM]
• led by Alan Rickinson (University of Birmingham, United Kingdom)
• In memory of Thomas Turse 1946-2018 (start to work on EBV since 1979s’ ; an oncologist; stromatolites-tumor in NPC; organizer of EBV meeting at Annecy France in 1994)

Patric Moore (Why Do Viruses Cause Cancer?)
Irving Weissman (Normal and Neoplastic Stem Cells)

0625 Monday (Day 2)

• EBV Infection and NPC Pathogenesis [06/25 AM]
• led by Alan Chiang (The University of Hong Kong, Hong Kong SAR China)

Paul Farrell (EBV Genome Sequence Variation: Geography, Function and Disease)
Bill Sugden (How EBV Prevails During Productive Infection)
Rebecca Skalsky (regulation of Host Signaling Pathways by EBV miRNAs)
Bo Zhao (NPC Epigenetic Landscapes and Super-Enhancers)
Selected from Poster Abstracts:
Lin Feng (Nasopharyngeal carcinoma susceptibility gene TNFRSF19 inhibits TGFß signaling and promotes tumorigenesis)
Miao Xu (Genome sequencing analysis identifies Epstein- Barr virus subtypes associated with the risk of nasopharyngeal carcinoma)

• Regulation of Lytic and Latent EBV Infection [06/25 PM]
• led by Mei-Ru Chen (National Taiwan University, Taiwan)

Shannon Kenney (Differentiation-Dependent Lytic EBV Reactivation in Epithelial Cells)
Lori Frappier (New Functions for EBV Proteins in Manipulating Cellular Processes Important for Cancer)
Mu Sheng Zeng 曾木聖 (The Key Cellular Factors in EBV Infection of Epithelial Cells)

0626 Tuesday (Day 3)

• Risk Factors and Novel Markers for NPC [06/26 AM]
• led by Jin-Xin Bei 貝錦新 (Sun Yat-Sen University Cancer Center, China)

Wei-Hua Jia (Genetic Predisposition of Nasopharyngeal Carcinoma: Evidence from GWAS and Sequencing Studies)
Jin-Ching Lin 林進清 (Application of Plasma EBV DNA Assay in Daily Practice of NPC Management)
Dennis Lo 盧煜明 (Plasma EBV DNA for – Screening Nasopharyngeal Carcinoma)
Maria Lung (New Insights in NPC Detection Utilizing Circulating Tumor Cell Enumeration and NGS Analysis)
Scott Bratman (Circulating Tumor DNA: Detection and Applications in Curable Cancers)

• Molecular Profiling of NPC [06/26 PM]
• led by Andrew Futreal (University of Texas MD Anderson Cancer Center, USA)

Kwok Wai Lo 羅國煒 (Acquired Genomic Changes in Nasopharyngeal Carcinoma)
Wei Dai (Genetic Susceptibility in Nasopharyngeal Carcinoma)
Daniel De Carvalho (Translational Aspects of DNA Methylation in Cancer)
Selected from Poster Abstracts:
Ming-Han Tsai 蔡明翰 (The M81 Epstein-Barr Virus Associated RNA2 Enhances CXCL8 Production and Spontaneous Virus Lytic Replication in Primary B Lymphocytes)

0627 Wed (Day 4)

• Tumor Microenvironment of NPC [06/27 AM]
• led by Eric Stanbridge (University of California, Irvine, USA)

Pierre Busson (Galectin-9 and Other Factors of Immune Escape in NPC Tumor Microenvironment: How to Bring Them Under Control?)

Maria Massucci (A Role of Bacterial Co-Infection in the Pathogenesis of NPC?)
Selected from Poster Abstracts:
Alan Chiang
(Novel Mechanism of Induction of Lytic Cycle of Epstein-Barr Virus (EBV) in EBV-Positive Epithelial Malignancies Through Intracellular Iron Chelation)
Scott Bratman

(EBV-Seq for Ultrassensitive Detection of Nasopharynx Cancer from Plasma Cell-Free DNA)
Shibing Li

(ISNLx Regulates Cellular Metabolic Reprogramming and Is a Potential Therapeutic Target for Nasopharyngeal Carcinoma)
Jun Zhang
(Epstein-Barr Virus-Encoded LMP1 Reprograms Glucose Metabolism to Drive Cell Motility Through mTORC2/PDHE1α-Mediated Histone Acetylation in Nasopharyngeal Cells)
Xuefeng Liu (ROCK inhbibitor J Pathol Author, Georgetown U)
(Patient-Derived Cell Models and Next Generation Living Biobanks (NGLB) for Precision Medicine)
Dewi Kartikawati Paramita
(NPC Strip G: Rapid Test Strip Detecting IgG Against EBV Antigens in NPC)

• Challenges and Novel Approaches in NPC Treatment [06/27 PM]
• led by Brian O'Sullivan (University of Toronto, Canada)

Danny Rischin (Role of Chemotherapy in NPC: Not Novel, but Still Challenging)

Jun Ma 馬駿 (Comprehensive Treatment Strategy in Locoregionally Advanced Nasopharyngeal Carcinoma)

Anne Lee (Challenges and Novel Approaches in Radiotherapy for Nasopharyngeal Carcinoma)

Troy Messick (Development of an EBNA1 Inhibitor for the Treatment of NPC: Toward First-in- Human Studies)

0628 Thu (Day 5)

• Immunotherapy of NPC [06/28 AM]
• led by Dora Kwong 鄺麗雲 (University of Hong Kong, Hong Kong SAR China)

Lillian Siu (Immune and Other Biomarkers of Resistance to Anti-PD1 Therapy in NPC)
Rajiv Khanna (Adoptive T Cell Therapy for NPC: Immune Correlates to Immune Contexture)
Graham Taylor (The NPC Immunotherapy Landscape)
Han Chong Toh (Cellular Immunotherapy for Nasopharyngeal Cancer: Learning from the Past for a Better Tomorrow)
Brigette Ma (Immune Checkpoint Inhibitor in the Treatment of Nasopharyngeal Carcinoma: A Clinical Overview)

• Keynote Session: Future Perspectives in NPC Research and Treatment
• led by Quynh-Thu Le (Stanford University, USA)

Tak Mak (Beyond Targeting Oncogenes: Future Anti-Cancer Strategies)
Lawrence Young (The Future of NPC Research: Opportunities and Challenges)

Poster List

17th Biennial EBV Meeting @ Switzerland (Aug/8-Aug/12)

有些abstract已被剪到GRC NPC個人檔案中

Monday, 2016/08/08 
Session 1: EBV epidemiology and sequence variation 2:30pm-
Chairpersons:
Henri-Jacques Delecluse, German Cancer Research Institute, Heidelberg, Germany

Alan Chiang, University of Hong Kong, China

1. Heterogeneity of the major internal repeat (IR1) of Epstein-Barr virus implicates interstrain recombination in pathogenesis, and includes a nonsense mutation of EBNA-LP in the prototype strain B95-8.
Mohammed Ba Abdullah, Imperial College London, UK
2. High levels of antibody that neutralize B-cell infection of Epstein-Barr virus and that bind EBV gp350 are associated with a lower risk of nasopharyngeal carcinoma
 Anna Coghill, National Cancer Institute, Bethesda, USA
3. Development of highly efficient and widely applicable CRISPR/Cas9-mediated cloning method of EBV genomes and its application to EBV-positive gastric cancer cell lines
 Teru Kanda, Aichi Cancer Center Research Institute, Nagoya, Japan
4. Association between cigarette smoking and oral EBV viral loads in China: a multicenter cross sectional study in 2013-2016
 Weihua Jia, Sun Yat-Sen University Cancer Center, Guangzhou, China
5. Determination and Genome-wide Analysis of EBV Sequences in EBV- associated Gastric Carcinoma from Guangdong, an endemic area of nasopharyngeal carcinoma 
Chun-kui Shao, Sun Yat-Sen University, Guangzhou, China
6. The dominating promoter variation of BRLF1 in nasopharyngeal carcinoma endemic area contributes to high efficacy of Epstein-Barr virus reactivation Jiangbo Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, China

GRC NPC Index Page | EBV Meeting

• Clevers, Hans
• Delecluse, Henri-Jacques
• Fuchs, Elaine
• Futreal, Andrew
• Hildesheim, Allan
• Lieberman, Paul M.
• Liu, Fei-Fei
• Lo, Kwok-Wei
• Lo, Yuk-Ming Dennis
• Longnecker, Richard
• Lu, Xin
• Ma, Jun | Ngan, Roger | Bei, Jin-Xin
• Rooney, Cliona
• Tsai, Ming-Han
• Tsao, George SH
• Zeng, Mu-Sheng
• zur Hausen, Harald
• Unclassified (Hong Zheng, Honglin Chen, Brigette Ma, Wei Dai | TESSA, TGFBRI inhibitor, BPLF1 DUB)
• Group Photo

EBV 2008 Symposium (更新)

曾益新廣東GD1 strain,ERTA有三個a.a. mutation,分別是P572(73%), Q489K(63%) and A377K);則有高達個分別是

9/2/2008 SFL wrote:
abstract submission deadline 是九月十五. 首頁在這裡.

曾毅是78歲的中國鼻咽癌開山始祖, 還有一篇 (NPC Vaccine, Published on Science news-August-29-2008)。